ClinicalTrials.gg
RecruitingNCT07687485TRIUMPHUpdated Nov 2, 2026

Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System

An interventional study of Transcatheter Tricuspid Valve Replacement (TTVR) with Laplace TTVR System and Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE TTVR System in Severe Tricuspid Valve Regurgitation, Tricuspid Valve Regurgitation and Tricuspid Valve Disease, sponsored by Laplace Interventional, Inc. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Laplace Interventional, Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 2, 2026Now RecruitingFirst site in United States+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 60 studies in Tricuspid Valve Insufficiency with a site in United States — 27 open to participants now, 36 under way, none of them phase 3. Tricuspid Valve Insufficiency · United States.

Planned enrollment
6th of 42
700 · median 63
Started
2026
with 9 others
No phase
39 of 60
18 open now
Primary completion
2029-09
later than 29 of 35 live
Registered
58th of 60
by date
Lead sponsor
2 of 60
Laplace Interventional, Inc

Among the 60 studies in Tricuspid Valve Insufficiency with a site in United States, this one is the 6th largest by planned enrollment of the 42 interventional ones that give a count, is one of 10 that started in 2026, is one of 39 with no phase, reaches primary completion later than 29 of the 35 other live ones, and was the 58th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

27 of the 60 studies in Tricuspid Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Tricuspid Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The objective of this clinical study is to assess the safety and efficacy of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of symptomatic subjects with at least severe tricuspid regurgitation (TR).

Read the detailed description

This study is a prospective, multi-center randomized (2:1) controlled pivotal trial to evaluate the safety and efficacy of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System compared to the Edwards EVOQUE TTVR System for the treatment of symptomatic subjects with severe or greater tricuspid regurgitation (TR).

03

Conditions studied

  • Severe Tricuspid Valve Regurgitation
  • Tricuspid Valve Regurgitation
  • Tricuspid Valve Disease
  • Cardiovascular Diseases (CVD)
  • Heart Valve Diseases
  • Tricuspid Valve Insufficiency
  • Severe Heart Valve Disease
  • Symptomatic Tricuspid Regurgitation
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 90 years of age at the time of the study procedure.
  • Symptomatic TR despite being adequately treated with OMT by the Local Heart Team for at least 30 days prior to the time of study consent.
  • Severe, massive or torrential tricuspid regurgitation determined by qualifying echocardiogram using the 5-grade classification.
  • Candidate felt suitable for transcatheter tricuspid valve replacement as determined by the local Heart Team and confirmed by the patient selection committee.
  • Subject has provided and agrees to return for all required post-procedure follow-up visits.
  • Anatomically suitable for the Laplace TTVR system.

Exclusion criteria

Exclusion Criteria:

  • Estimated of less than 12 months.
  • Need for emergent, urgent or planned surgery or intervention within 30 days following the study procedure. Planned or scheduled cardiac surgery within next 12 months.
  • Severe renal insufficiency defined as \<25 mL/min or requiring chronic renal replacement therapy at the time of screening committee review.
  • Current history (within last 5 years) of illicit drug use.
  • Stroke or other major cerebrovascular event within 90-days prior to index procedure.
  • Current or planned pregnancy within next 12 months for women of .
  • Participation in another pre-market device study or investigational drug study for a cardiac related drug.
  • Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements. Any patient considered to be vulnerable.
  • Anatomically unsuitable for the Laplace TTVR System
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    Laplace TTVR System

    Transcatheter tricuspid valve replacement with the Laplace TTVR System in patients with severe or greater TR.

    Device: Transcatheter Tricuspid Valve Replacement (TTVR) with Laplace TTVR System

  • Active comparator
    Edwards EVOQUE TTVR

    Transcatheter tricuspid valve replacement with the Edwards EVOQUE TTVR in patients with severe or greater TR.

    Device: Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE TTVR System

  • Experimental
    Laplace TTVR System Single Arm Cohort

    Transcatheter tricuspid valve replacement with Laplace TTVR System in patients with severe or greater tricuspid regurgitation who are deemed ineligible to be treated with the Active Comparator EVOQUE TTVR and are suboptimal T-TEER candidates.

    Device: Transcatheter Tricuspid Valve Replacement (TTVR) with Laplace TTVR System

Interventions

  • DeviceTranscatheter Tricuspid Valve Replacement (TTVR) with Laplace TTVR System

    Transcatheter Tricuspid Valve Replacement

  • DeviceTranscatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE TTVR System

    Transcatheter Tricuspid Valve Replacement

06

What researchers measure

Primary outcomes

  1. Composite of major adverse events (MAEs)

    A composite of major adverse events (MAEs) at 30 days consisting of the following components: * Cardiovascular mortality * Myocardial infarction (MI) * All stroke * New need for renal replacement therapy * Severe bleeding (includes type 3b or higher as defined by Tricuspid Valve Academic Research Consortium \[TVARC\]) * Non-elective tricuspid valve re-intervention, surgery or transcatheter * Major access site and vascular complications * Major cardiac structural complications * Device-related pulmonary embolism * New arrhythmia or conduction disorder requiring permanent pacing

    Time frame: 30 days post-procedure

  2. Composite 12-Month Endpoint: All-cause mortality, heart failure hospitalization, tricuspid valve re-intervention

    12-month composite of all-cause mortality, heart failure hospitalization, tricuspid valve re-intervention

    Time frame: 12 months post-procedure

Secondary outcomes

  1. Change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS) ≥ 10 points from baseline to 12 months

    Scores range from 0-100, with higher scores generally indicating higher quality of life related to heart failure.

    Time frame: 12 months post-procedure

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2029, 36 months after the start.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 36 months is close to that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 7, 2026
StartActual
Sep 4, 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2038
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 2, 2026
Sites
2 sites added — first site in United States
Show 2 added (2 United States)
  • Oklahoma Heart Institute · Tulsa, United States
  • Ballad Health · Kingsport, United States
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in United States
    Show 2 added (2 United States)
    • Oklahoma Heart Institute · Tulsa, United States
    • Ballad Health · Kingsport, United States
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07687485
Lead sponsor
Laplace Interventional, Inc
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
Sep 4, 2026
Primary completion
Sep 2029 (estimated)
Completion
Sep 2038 (estimated)
Last update
Nov 2, 2026

Study contacts

Ryan Gladney
Contact
clinical@laplaceint.com
763-710-3539
Kashish Goel, MD
principal investigator · Vanderbilt University Medical Center
Brandon Jones, MD
principal investigator · Providence St. Vincent Medical Center
Charanjit Rihal, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion